218 related articles for article (PubMed ID: 29444073)
1. Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia.
Hall MT; Simms KT; Lew JB; Smith MA; Saville M; Canfell K
PLoS One; 2018; 13(2):e0185332. PubMed ID: 29444073
[TBL] [Abstract][Full Text] [Related]
2. The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications.
Hall MT; Smith MA; Lew JB; O'Hallahan J; Fentiman G; Neal H; Sage M; Canfell K
Gynecol Oncol; 2019 Mar; 152(3):472-479. PubMed ID: 30876491
[TBL] [Abstract][Full Text] [Related]
3. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
[TBL] [Abstract][Full Text] [Related]
4. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
Velentzis LS; Caruana M; Simms KT; Lew JB; Shi JF; Saville M; Smith MA; Lord SJ; Tan J; Bateson D; Quinn M; Canfell K
Int J Cancer; 2017 Dec; 141(12):2410-2422. PubMed ID: 28801947
[TBL] [Abstract][Full Text] [Related]
5. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.
Lew JB; Simms KT; Smith MA; Hall M; Kang YJ; Xu XM; Caruana M; Velentzis LS; Bessell T; Saville M; Hammond I; Canfell K
Lancet Public Health; 2017 Feb; 2(2):e96-e107. PubMed ID: 29253402
[TBL] [Abstract][Full Text] [Related]
6. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
[TBL] [Abstract][Full Text] [Related]
8. Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use.
Smith MA; Gertig D; Hall M; Simms K; Lew JB; Malloy M; Saville M; Canfell K
BMC Health Serv Res; 2016 Apr; 16():147. PubMed ID: 27112193
[TBL] [Abstract][Full Text] [Related]
9. The impact of HPV vaccination on future cervical screening: a simulation study of two birth cohorts in Denmark.
Hestbech MS; Lynge E; Kragstrup J; Siersma V; Vazquez-Prada Baillet M; Brodersen J
BMJ Open; 2015 Aug; 5(8):e007921. PubMed ID: 26275901
[TBL] [Abstract][Full Text] [Related]
10. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
Adams M; Jasani B; Fiander A
Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
[TBL] [Abstract][Full Text] [Related]
11. Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study.
Castanon A; Landy R; Pesola F; Windridge P; Sasieni P
Lancet Public Health; 2018 Jan; 3(1):e34-e43. PubMed ID: 29307386
[TBL] [Abstract][Full Text] [Related]
12. Impact of human papillomavirus age-related prevalence and vaccination levels on interpretation of cervical screening modalities: a modelling study.
Grimes DR
BMJ Open; 2024 Feb; 14(2):e078551. PubMed ID: 38309749
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
14. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
15. Estimated Number of Cases of High-Grade Cervical Lesions Diagnosed Among Women - United States, 2008 and 2016.
McClung NM; Gargano JW; Park IU; Whitney E; Abdullah N; Ehlers S; Bennett NM; Scahill M; Niccolai LM; Brackney M; Griffin MR; Pemmaraju M; Querec TD; Cleveland AA; Unger ER; Markowitz LE;
MMWR Morb Mortal Wkly Rep; 2019 Apr; 68(15):337-343. PubMed ID: 30998672
[TBL] [Abstract][Full Text] [Related]
16. HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer.
Ogilvie GS; Krajden M; van Niekerk D; Smith LW; Cook D; Ceballos K; Lee M; Gentile L; Gondara L; Elwood-Martin R; Peacock S; Stuart G; Franco EL; Coldman AJ
Int J Cancer; 2017 Jan; 140(2):440-448. PubMed ID: 27685757
[TBL] [Abstract][Full Text] [Related]
17. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
[TBL] [Abstract][Full Text] [Related]
18. HPV testing and vaccination in Europe.
Leeson SC; Alibegashvili T; Arbyn M; Bergeron C; Carriero C; Mergui JL; Nieminen P; Prendiville W; Redman CW; Rieck GC; Quaas J; Petry KU
J Low Genit Tract Dis; 2014 Jan; 18(1):61-9. PubMed ID: 23774078
[TBL] [Abstract][Full Text] [Related]
19. The road to cervical cancer elimination in Malaysia: Evaluation of the impact and cost-effectiveness of human papillomavirus screening with self-collection and digital registry support.
Keane A; Ng CW; Simms KT; Nguyen D; Woo YL; Saville M; Canfell K
Int J Cancer; 2021 Dec; 149(12):1997-2009. PubMed ID: 34363620
[TBL] [Abstract][Full Text] [Related]
20. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
